Loading…
Loading…
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Q2 2026 Earnings Call Transcript
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Q1 2026 Earnings Call Transcript
MEXICO CITY, April 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter 2026.
MEXICO CITY, April 13, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company") today announced that it will report its First Quarter 2026 Earnings Results on Wednesday, April 22, 2026, after the Mexican Stock Exchange (BMV) close.
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Q4 2025 Earnings Call Transcript
MEXICO CITY, Feb. 25, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the fourth quarter and full year 2025.
MEXICO CITY, Jan. 30, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company") today announced that it will report its Fourth Quarter 2025 Earnings Results on Wednesday, February 25, 2026, after the Mexican Stock Exchange (BMV) close.
MEXICO CITY , Dec. 23, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, informs that today it completed the payment of the cash dividend previously announced through a Notice of Rights filed with the Mexican Stock Exchange (Bolsa Mexicana de Valores).
No recent filings indexed.